Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 18 and 75 years.~* Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.~* Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).~* Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).~Exclusion Criteria:~* Have non-plaque forms of psoriasis.~* Drug-induced psoriasis.~* Current active infection.~* Infected with Mycobacterium tuberculosis (TB).~* Have any history of malignancies.~* Require treatment with prohibited concomitant medications(s).~* Positive for hepatitis B or C, or human immunodeficiency virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06826647 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Placebo (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
- PF-06826647 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 16 weeks then for 24 weeks in Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).